Articles from Frontier Medicines Corporation

Frontier Medicines Corporation (Frontier), a clinical-stage, AI-powered precision medicines company that discovers and develops covalent medicines for previously undruggable and hard-to-drug disease-causing targets, starting with cancer, today announced that it will present preclinical data from its FMC-242 program at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18–20. FMC-242 is a novel, orally bioavailable, covalent allosteric breaker of the PI3Kα-RAS interaction designed using Frontier’s proprietary, AI-powered CovalentAI™ Platform. PI3Kα is the second most frequently mutated oncogene in human cancer and plays an essential role in both PI3Kα and RAS-driven cancers.

Frontier Medicines Corporation (Frontier), a clinical-stage, AI-powered precision medicines company that discovers and develops covalent medicines for previously undruggable and hard-to-drug disease-causing targets, starting with cancer, today announced that the U.S. Food and Drug Administration (FDA) has allowed Frontier to proceed to human clinical trials under an Investigational New Drug (IND) application for FMC-242 for the treatment of select advanced solid tumors. FMC-242 is a novel, orally bioavailable, covalent allosteric breaker of the PI3Kα-RAS interaction designed using Frontier’s proprietary, AI-powered CovalentAI™ platform. The allowance enables Frontier to initiate a Phase 1/2 clinical trial evaluating FMC-242 as monotherapy and in combination with other targeted therapies in patients with advanced or metastatic solid tumors.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced three appointments to its leadership team: Aaron Weitzman, M.D., as Chief Medical Officer; Mike Preigh, Ph.D., as Chief Technical Operations Officer; and Joelle Lufkin, M.P.H., as Senior Vice President, Clinical Development and Strategy.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the appointment of David R. Epstein to its board of directors. Mr. Epstein currently serves as chairman and chief executive officer of Ottimo Pharma and was most recently chief executive officer of Seagen, where he led the company through a period of significant growth and innovation, culminating in its acquisition by Pfizer in 2023.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, announced that the Company has granted LG Chem, Ltd. ("LG Chem"), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, an exclusive worldwide license to develop and commercialize FMC-220 outside of Greater China, with Frontier retaining ownership and full control in Greater China. FMC-220 is Frontier’s first-in-class covalent p53 Y220C activator being evaluated for the treatment of solid tumor cancers with TP53 loss-of-function mutations.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that it will present preclinical data on its FMC-242 program, as well as advances from its AI-powered Frontier™ Platform, at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego. FMC-242 is Frontier’s first-in-class allosteric breaker of the PI3Kα-RAS interaction that is in preclinical development for the treatment of solid tumors driven by RTK activation, RAS mutations and PI3Kα mutations, as both a single agent and in combination with other therapies including KRAS inhibitors.